Nonalcoholic Fatty Liver Disease clinical trials
68 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- Effect of Ketone Esters on Liver Fat Content and Metabolic Function
- Evaluating the Pharmacokinetics and Safety of Miricorilant
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
- Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
- Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
- Milk Thistle Clinical Trial in Pediatric NAFLD
- Intermittent Fasting for NAFLD in Adults
- A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
- A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
- Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
- A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
- A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- Michigan Weight Navigation Program (MiWeigh) Study
- Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
- Corazones Unidos Study
- Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
- Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
- Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
- A Study of Electronic Clinical Decision Support Tools for Steatotic Liver Disease
- The Olmsted NAFLD Epidemiology Study (TONES)
- Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD
- Accurate Point of Care Liver Disease Diagnostics (Phase 2)
- Thermoacoustic Method for Estimating Liver Fat Fraction
- Pediatric Metabolic Dysfunction-associated Steatotic Liver Disease and Food Insecurity
- Quantitative Ultrasound to Assess Steatotic Liver Disease in Children
- AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
- Endoscopic Ultrasound Shear Wave Elastography Study
- Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
- Androgens and NAFLD Longitudinal Cohort Study
- Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
- InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
- Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
- NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease
- NAFLD Clinical Care Pathway
- Reversal of Lipid-Induced Insulin Resistance
- Food Insecurity and MASLD: A Fruit and Vegetable Intervention Study
- Quantifying Hepatic Mitochondrial Fluxes in Humans
- Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- Advanced Fibrosis Detection for MASLD in Primary Care
- Human Models of Selective Insulin Resistance: Alpelisib, Part I
- Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
- Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer
- Effect of Insulin Lowering on Lipogenesis
- Implementing Food Referrals for Equity and Sustained Health
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Nonalcoholic Fatty Liver Disease” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.